XML 98 R50.htm IDEA: XBRL DOCUMENT v3.25.1
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Narrative) (Details)
1 Months Ended 12 Months Ended
Apr. 06, 2018
USD ($)
milestone
Apr. 05, 2018
USD ($)
option
Sep. 30, 2019
USD ($)
performanceObligation
material_right
Dec. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Accounts receivable       $ 526,000 $ 923,000
Deferred revenues       7,556,000 0
Kite Pharma, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Increase (decrease) in revenue         13,900,000
Increase (decrease) in net loss         $ 13,900,000
Increase (decrease) in basic net loss per share | $ / shares         $ 0.08
Increase (decrease) in diluted net loss per share | $ / shares         $ 0.08
Kite Pharma, Inc. | License          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contract with customer liability   $ 150,000,000      
Number of remaining performance obligations | performanceObligation     4    
Number of material rights for renewal of research period | material_right     2    
Renewal period     1 year    
Fixed consideration     $ 150,000,000    
Kite Pharma, Inc. | Collaboration and License Agreement          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Milestone payments received $ 150,000,000        
Initial research term of agreement   6 years      
Number of options to extend initial research term | option   2      
Extended research term of agreement   1 year      
Separate fee for additional term   $ 10,000,000      
Accounts receivable       0 $ 200,000
Deferred revenues       0 $ 0
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contingent development and sales-based milestone payments to be received 1,300,000,000        
Kite Pharma, Inc. | Collaboration and License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Contingent development and sales-based milestone payments to be received $ 1,800,000,000        
Maximum amount of achieved milestones to receive payment | milestone 10        
Kite Pharma, Inc. | Collaboration and License Agreement | Maximum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Development and sales-based milestone payments to be received $ 3,000,000,000        
Kite Pharma, Inc. | Collaborative Arrangement | Change in Agreement Estimate, March and September 2023          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Increase (decrease) in revenue       13,900,000  
Increase (decrease) in net loss       $ 13,900,000  
Increase (decrease) in basic net loss per share | $ / shares       $ 0.08  
Increase (decrease) in diluted net loss per share | $ / shares       $ 0.08